Form 4: Vigil Neuroscience Director Mary Thistle Receives Stock Option Award

Director Mary Thistle of Vigil Neuroscience, Inc. was granted a stock option award for 18,068 shares on June 5, 2024.

Summary

• Mary Thistle, a director at Vigil Neuroscience, Inc., received a stock option award on June 5, 2024.
• The award is for 18,068 shares of common stock.
• The exercise price of the option is $3.38 per share.
• The option vests on the earlier of June 5, 2025, or the next annual meeting of the Issuer's stockholders.
• The option expires on June 5, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for company leadership.

Positives

• The stock option award aligns the director's interests with those of the shareholders, incentivizing her to work towards increasing the company's value.

Industry Context

Stock option awards are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in publicly traded companies, particularly in the biotech sector.
• The size of the grant (18,068 shares) would need to be compared to similar grants at peer companies of similar market capitalization and stage of development to determine if it is within industry norms.
• Companies like Biohaven, Amylyx Pharmaceuticals, and Denali Therapeutics also use stock options as part of their compensation packages for directors and executives.

Stakeholder Impact

• Shareholders may view the stock option award as a positive incentive for the director.
• Employees may see this as a sign of the company's commitment to its leadership.

Key Dates